Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | APEX1 | P27695 | 1/20 | 0.31 |
| ▸ | THPO | P40225 | 1/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14794931 | 0.89 | MEN1 (0.33) | MEN1KMT2ALMNACYP3A4CYP2C9 | |
| SCHEMBL13513547 | 0.84 | — | — | |
| SCHEMBL12990908 | 0.81 | MEN1 (0.35) | MEN1KMT2ALMNACYP3A4CYP2C9 | |
| SCHEMBL1799869 | 0.79 | ALDH1A1 (0.46) | MEN1KMT2ALMNACYP2C9TSHR | |
| SCHEMBL10034491 | 0.78 | ALDH1A1 (0.44) | MEN1KMT2ALMNATSHR | |
| SCHEMBL1764576 | 0.78 | KMT2A (0.49) | MEN1KMT2ALMNACYP3A4CYP2C9 | |
| SCHEMBL2147485 | 0.78 | CYP3A4 (0.35) | MEN1KMT2ALMNACYP3A4CYP2C9 | |
| SCHEMBL836758 | 0.77 | ALDH1A1 (0.33) | MEN1KMT2ALMNACYP3A4CYP2C9 | |
| SCHEMBL13369011 | 0.76 | LPAR5 (0.37) | MEN1KMT2ALMNACYP3A4 | |
| SCHEMBL10052377 | 0.76 | ALDH1A1 (0.37) | MAPK1MEN1KMT2ALMNATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190201528-A1 | Derivatized Hyperbranched Polyglycerols | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2019-07-04 | — | — | US | disclosed |
| US-20170319696-A1 | Derivatized Hyperbranched Polyglycerols | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2017-11-09 | — | — | US | disclosed |
| US-20170319696-A1 | Derivatized Hyperbranched Polyglycerols | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2017-11-09 | — | — | US | disclosed |
| US-9561278-B2 | Derivatized hyperbranched polyglycerols | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2017-02-07 | — | — | US | disclosed |
| US-9561278-B2 | Derivatized hyperbranched polyglycerols | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2017-02-07 | — | — | US | disclosed |
| US-20160114040-A1 | Derivatized Hyperbranched Polyglycerols | CENTRE FOR DRUG RESEARCH AND DEVELOPMENT (CA) | 2016-04-28 | — | — | US | disclosed |
| US-20160114040-A1 | Derivatized Hyperbranched Polyglycerols | CENTRE FOR DRUG RESEARCH AND DEVELOPMENT (CA) | 2016-04-28 | — | — | US | disclosed |
| US-9186410-B2 | Derivatized hyperbranched polyglycerols | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2015-11-17 | — | — | US | disclosed |
| US-9186410-B2 | Derivatized hyperbranched polyglycerols | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2015-11-17 | — | — | US | disclosed |
| US-20130122112-A1 | Derivatized Hyperbranched Polyglycerols | CENTRE FOR DRUG RESEARCH AND DEVELOPMENT (CA) | 2013-05-16 | — | — | US | disclosed |
| US-20130122112-A1 | Derivatized Hyperbranched Polyglycerols | CENTRE FOR DRUG RESEARCH AND DEVELOPMENT (CA) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160114040-A1 | Derivatized Hyperbranched Polyglycerols | DDOST, UGCG, DAD1 | MAPK1 4709/4885MEN1 1700/4885KMT2A 3642/4885 |
| US-20130122112-A1 | Derivatized Hyperbranched Polyglycerols | DDOST, UGCG, DAD1 | MAPK1 4709/4885MEN1 1700/4885KMT2A 3642/4885 |
| US-20190201528-A1 | Derivatized Hyperbranched Polyglycerols | DDOST, UGCG, DAD1 | MAPK1 4709/4885MEN1 1700/4885KMT2A 3642/4885 |
| US-20170319696-A1 | Derivatized Hyperbranched Polyglycerols | DDOST, UGCG, DAD1 | MAPK1 4709/4885MEN1 1700/4885KMT2A 3642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.